FibroGen (NASDAQ:FGEN) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of FibroGen (NASDAQ:FGEN) in a report released on Thursday morning. The firm issued a hold rating on the biopharmaceutical company’s stock.

Separately, William Blair reiterated a “market perform” rating on shares of FibroGen in a report on Wednesday.

FibroGen Stock Down 9.5 %

Shares of FGEN traded down $0.04 during mid-day trading on Thursday, hitting $0.33. 1,741,274 shares of the company traded hands, compared to its average volume of 2,228,614. FibroGen has a 1-year low of $0.18 and a 1-year high of $2.93. The company has a market capitalization of $33.72 million, a PE ratio of -0.28 and a beta of 0.72. The business has a 50 day moving average of $0.37 and a 200 day moving average of $0.72.

FibroGen (NASDAQ:FGEN) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.38) by $0.21. The company had revenue of $46.33 million for the quarter, compared to analyst estimates of $34.00 million. During the same quarter last year, the company earned ($0.52) EPS. As a group, research analysts expect that FibroGen will post -1.12 EPS for the current fiscal year.

Hedge Funds Weigh In On FibroGen

Hedge funds and other institutional investors have recently bought and sold shares of the business. Cubist Systematic Strategies LLC increased its holdings in FibroGen by 3,906.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 287,332 shares of the biopharmaceutical company’s stock worth $256,000 after buying an additional 280,161 shares during the period. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of FibroGen during the 1st quarter worth approximately $131,000. Acadian Asset Management LLC grew its stake in shares of FibroGen by 1.4% during the 1st quarter. Acadian Asset Management LLC now owns 2,503,865 shares of the biopharmaceutical company’s stock worth $5,883,000 after purchasing an additional 34,937 shares during the period. Point72 DIFC Ltd grew its stake in shares of FibroGen by 734.2% during the 2nd quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 45,990 shares during the period. Finally, XTX Topco Ltd acquired a new stake in shares of FibroGen during the 2nd quarter worth approximately $424,000. Institutional investors and hedge funds own 72.71% of the company’s stock.

FibroGen Company Profile

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.